generic glp 1 drugs Connecticut could make history as first state to manufacture its own GLP-1 List of approved and pending
Description
They typically induce a 15 % to 20 % weight reduction
The SUSTAIN-7 trial was a randomized, open-label, active-controlled, parallel, four-armed trial
Clinical trials show semaglutide produces approximately 15% average body weight loss, while Saxenda (liraglutide) produces 5-8% on average
Beta-2 agonists used by all other routes of administration remain prohibited at all times
But how do they compare to bariatric surgery, the long-established and most effective treatment for obesity
